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1. Introduction 
Sjögren’s syndrome (SS) is a chronic autoimmune disease characterised by epithelial cell 
destruction and by peri-epithelial B and T lymphocytic infiltration of multiple organ targets, 
and particularly of the exocrine glands. Salivary and lachrymal glands are emblematically 
involved, with dry mouth (xerostomia) and dry eyes (xerophtalmia) representing the clinical 
hallmarks of the disease. Moreover, despite the dominance of T cells in the glandular 
lesions, B cell activation plays a very prominent role as demonstrated by the presence of 
serum hypergammaglobulinemia, by the occurrence of a wide spectrum of autoantibodies 
(i.e., antinuclear antibodies, anti-Ro/SSA and anti-La/SSB antibodies, and Rheumatoid 
factor) and, in some cases, by the development of B cell lymphomas. High-throughput mass 
spectrometry approaches coupled with different separation techniques have been applied to 
several human rheumatic diseases in order to discover biomarkers and therapeutic targets 
by studying the proteome of biological fluids. We will describe our results obtained up to 
now on the proteomic analysis of whole saliva, particularly on how to distinguish primary 
and secondary SS manifestations. Moreover, we will report on the state of the art of 
proteomic studies of other biological fluids and of parotid gland tissues, focusing on the 
potentiality of proteomic applications in defining a panel of biomarkers useful in the 
diagnosis and therapy strategy of SS. 
2. Clinical aspects 
SS is a chronic inflammatory disease characterised by an autoimmune exocrinopathy of the 
lachrymal and salivary glands due to lymphocytic infiltrations. SS typically presents as dry 
eyes (xerophthalmia) and dry mouth (xerostomia). This process can manifest either as the 
independent phenomenon of primary SS or as a secondary when found in the context of 
another autoimmune process, most commonly rheumatoid arthritis, systemic lupus 
erythematosus or systemic sclerosis (Ramos-Casals et al., 2005a; Kassan & Moutsopoulos, 
2004). Given the overlap of SS with many other rheumatic disorders, it is sometimes difficult 
to determine whether a clinical manifestation is a consequence of only SS or is due to one of 
its overlapping disorders.  
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2.1 Incidence and causes of Sjögren’s syndrome 
With a population prevalence ranging from 0.5 to 3%, SS appears to be a rather common 
disease (Binard et al., 2007). SS can develop at any age, but is most common in elderly 
people. Onset typically occurs in the fourth to fifth decade of life. It is frequent in women, 
who account for 9 out of 10 cases. The cause of SS remains unknown, but there is growing 
scientific support for genetic (inherited) and environmental factors. The presence of 
activated salivary gland epithelial cells expressing Major Histocompatibility Complex class 
II molecules and the identification of inherited susceptibility markers suggest that 
environmental or endogenous antigens trigger a self-perpetuating inflammatory response in 
susceptible individuals. Viruses are possible candidates for environmental triggers since 
Sjögren-like syndromes are seen in patients infected with HIV, hepatitis C and HTLV-1. 
Damage and/or cell death due to viral infection or other causes may provide triggering 
antigens to Toll-like receptors in or on dendritic or epithelial cells, which, by recognising 
pathogen-associated patterns, are activated and begin producing cytokines, chemokines, 
and adhesion molecules. As T and B lymphocytes migrate into the gland, they themselves 
become activated by dendritic and epithelial cells, thereafter acting as antigen-presenting 
cells (Fox, 2005). Expressed antigens include SSA/Ro, SSB/La, alpha-fodrin and beta-fodrin, 
or cholinergic muscarinic receptors (Gottenberg et al., 2003). Recent studies suggest that the 
disease process of SS has a neuroendocrine component. Proinflammatory cytokines released 
by epithelial cells and lymphocytes may impair neural release of acetylcholine. In addition, 
Bolstad and colleagues (Bolstad et al., 2003) have focused on the role of apoptotic 
mechanisms in the pathogenesis of primary SS. A defect in Fas-mediated apoptosis, which is 
necessary for down-regulation of the immune response, can result in a chronic 
inflammatory destruction of the salivary gland, resembling SS. 
2.2 Symptoms of Sjögren’s syndrome 
Symptoms of SS can involve the glands and /or other organs of the body (extra glandular 
manifestations). Glandular or exocrine manifestations of SS result from the periepithelial 
lymphocytic infiltration of the salivary and lacrimal glands. Inflammation of the salivary 
glands can lead to mouth dryness, swallowing difficulties, dental decay, cavities, gum 
disease, mouth sores and swelling, and stones and/or infection of the parotid gland. Dry 
lips often accompany the mouth dryness. Extraglandular problems in SS include joint pain 
or inflammation, Raynaud's phenomenon, lung inflammation, lymph node enlargement, 
and kidney, nerve and muscle disease. A rare serious complication of SS is inflammation of 
the blood vessels (vasculitis), which can damage body tissues supplied by these vessels. A 
common disease that is occasionally associated with SS is autoimmune thyroiditis 
(Hashimoto's thyroiditis), while a small percentage of patients with SS develop cancer of the 
lymph glands (lymphoma). 
2.3 Diagnosis of Sjögren’s syndrome and classification criteria 
At present, the diagnosis of SS is based upon the combination of several clinical, serological, 
histological, and instrumental elements suggestive of both exocrine gland involvement and 
of typical laboratory abnormalities (antibodies anti-Ro/SSA and La/SSB). From a practical 
point of view, the diagnosis can be made according to the “American-European Consensus 
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Group Revised Classification Criteria, which were published in 2002 (Vitali et al., 2002) and 
revised in 2010 (Seror et al., 2010). Before their elaboration, there were several different 
concomitant criteria sets, varying in their emphasis, mostly on laboratory tests, on clinical 
features of dry eye and dry mouth, or on both. At that time, there was no uniform 
agreement on the diagnosis of primary SS, with substantial confusion in research 
publications and clinical-trial reports. The Revised Criteria exhibit approximately 95% 
sensitivity and specificity for SS, and due to their high specificity and sensitivity, they can be 
used as diagnostic criteria. They encompass the presence of subjective and objective sicca 
manifestations, antibodies to Ro/SS-A and La/SS-B antigens, and characteristic 
histopathologic findings in minor salivary glands with an average of 50 or more 
lymphocytes (focus) per 4 mmq of minor salivary gland samples. Of the 6 given criteria, 4 
must be present to establish a diagnosis of SS, with 1 of the 4 being an objective 
measurement (i.e., by histopathologic examination or antibody screening) (Vitali et al., 
2002). In their present state, the Classification Criteria are insufficient to make a clear 
diagnosis, and a certain proportion of patients may be misclassified, particularly in the early 
stages of the disorder, when the typical signs and symptoms are often lacking or are not 
entirely expressed. On the other hand, early diagnosis is crucial in avoiding destructive 
processes that frequently lead to a poor quality of life and early invalidity (Gran, 2002). 
Moreover, there is quite a weak correlation between clinical symptoms and the 
exocrinopathy measurements, and the assessment of organ involvement is currently limited 
to general markers of inflammation or organ function and needs profound improvement 
(Hay et al., 1998). Finally, no specific predictive factors of flares, disease relapses or disease 
outcomes have been described yet, even if unfavourable predictors have been thoroughly 
investigated, especially for lymphoproliferative disorders, which are the most serious 
complication in patients with SS (Gran, 2002; Manganelli et al., 2006; Voulgarelis et al., 1999). 
2.4 Extra-glandular Sjögren’s syndrome involvement 
SS involves primarily the exocrine glands. Extraglandular involvement falls into two general 
categories. Peri-epithelial infiltrative processes include interstitial nephritis, liver 
involvement, and bronchiolitis, and generally follow a benign course. Extra-epithelial extra-
glandular involvement in SS is related to B-cell hyper-reactivity, hyper-
gammaglobulinemia, and immune complex formation, and includes palpable purpura, 
glomerulonephritis, and peripheral neuropathy. These latter manifestations occur later in 
the course of SS and are associated with a higher risk of transformation to lymphoma 
(Tzioufas & Voulgarelis, 2007). The incidence of systemic vasculitis manifestation in SS is 
approximately 5-10% of patients with SS (Ramos-Casals et al., 2005b). Skin involvement 
mainly manifests in the form of vasculitis cutaneous purpura. These lesions are clinically 
identical to those found in patients affected by systemic lupus erythematosus. In addition, 
Raynaud’s phenomenon is a vascular condition with an incidence of 13% in patients with SS 
(Bayetto & Logan, 2010). 
3. Applicability of proteomic to study rheumatic diseases 
Proteomic approaches are expanding our ability to determinate changes in protein 
expression, and the technology used has rapidly evolved over the last decade allowing for 
more accurate quantitation of the differentially expressed proteins (Vanarsa & Mohan, 
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2010). In rheumatology, the application of proteomic in the search for potential biomarkers 
of the disease has produced a high number of reports concerning different diseases such as 
rheumatoid arthritis, systemic lupus erythematosus, ankylosing spondylitis, osteoarthritis, 
333systemic sclerosis, and SS. Depending on the nature of the rheumatic disease, the choice 
of samples include saliva, serum, synovial fluid, urine, blood cells, cell lines (chondrocytes, 
synoviocytes, fibroblasts) or tissues (parotid glands, articular tissue, cartilage). Moreover, 
new applications have been found such as cerebro-spinal fluid in multiple sclerosis, 
peritoneal dialysate and haemodialysis fluid, broncoalveolar lavage fluid in interstitial lung 
disease. The aims have been to add new information about the disease pathogenesis and to 
identify protein biomarkers for non-invasive diagnosis, staging, and monitoring. A list of 
proteomic studies performed in rheumatic diseases in the last ten years is shown in table 1. 
Together, these studies underline the potentiality and applicability of proteomic in the study 
of rheumatic diseases. Unfortunately, there have not been any studies so far that have 
identified a panel of biomarkers with high specificity and sensitivity able to diagnose and 
predict rheumatic diseases.  
 
Rheumatic diseases References Samples Proteomic approach 
Osteoartritis De Ceuninck 
et al., 2005 
cartilage 2DE/tandem MS 
 Ruiz-Romero et 
al., 2005 
chondrocytes 2DE/MALDI-TOF 
 Gobezie  
et al., 2007 
synovial fluid 1DE/electrospray ionization 
tandem MS (LC-ESI-MS) 
 
 Wu et al., 2007 
 
cartilage 2DE/nano-LC-tandem MS 
 Guo et al., 2008 cartilage 2DE/linear ion trap-Fourier 
transform ion cyclotron 
resonance mass spectrometry 
 Lambrecht  
et al., 2008 
cartilage 2DE/tandem MS 
 
 Rosenthal  
et al., 2011 
cartilage nano-LC-tandem MS  
 de Seny  
et al., 2011 
serum SELDI-TOF-MS 
 Ma et al., 2011 cartilage 2DDIGE/MALDI/TOF/MS 
Spondyloarthritis Tilleman  
et al., 2005 
synovium 2DE/MALDI-TOF-ESI, 
tandem MS 
 Wright  
et al., 2009 
monocytes 2-DE/MALDI-TOF-MS 
 Liu et al., 2007 serum ESI-Q-TOF MS/MS 
 Li et al., 2010 serum 2-DE/MALDI-TOF-MS 
 Li et al., 2010 peripheral blood 
mononuclear cells 
2-DE/MALDI-TOF-MS 
Rheumatoid Arthritis Sinz et al., 2002
 
serum, synovial 
fluid 
2DE/MS 
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Rheumatic diseases References Samples Proteomic approach 
 Liao et al., 2004 serum, synovial 
fluid 
LC/MS/MS 
 Drynda  
et al., 2004 
serum, synovial 
fluid 
2DE/MS 
 de Seny  
et al., 2005 
serum SELDI-TOF-MS 
 Hueber  
et al., 2005 
serum antigen-microarrays 
 Kim et al., 2006 synovial fluid 2DE/MALDI-TOF 
 Matsuo  
et al., 2006 
synovium 2DE/MALDI-TOF 
 Schulz  
et al., 2007 
peripheral blood 
mononuclear cells 
2DE/MALDI-TOF 
 
 Hueber  
et al., 2007 
serum antigen- microarrays 
 de Seny  
et al., 2008 
serum SELDI-TOF-MS 
 Zheng  
et al., 2009 
plasma capillary reversed-phase –
HPLC/ion trap-FT-MS 
 Chang  
et al., 2009 
synovial tissues 2DE/MALDI-TOF 
 
 Bo et al., 2009 synovial fibroblasts 2DE/MALDI-TOF-MS 
 Giusti  
et al., 2010 
saliva 2DE/MALDI-TOF-MS 
 
 Li et al., 2010 serum 2DE/MALDI-TOF-MS 
 Baillet  
et al., 2010 
synovial fluid SELDI-TOF-MS 
 Matsuo  
et al., 2011 
synoviocytes phoshoproteomic 
Wegener’s 
Granulomatosis 
Stone  
et al., 2005 
serum SELDI-TOF-MS 
Systemic Sclerosis Fietta  
et al., 2006 
bronchoalveolar 
fluid 
2DE/MALDI-TOF 
LC/MS/MS 
 Giusti  
et al., 2007 
saliva 2DE/MALDI-TOF 
 Aden  
et al., 2008 
skin 2DE /MALDI-TOF 
 Scambi  
et al., 2010 
serum 2DE/MALDI-TOF-MS 
+ Lupus erithematosus 
systemic 
Carlsson  
et al., 2011 
serum antibody microarray 
Lupus erithematosus 
systemic 
Pavon et al., 
2006 
plasma 2DE/MALDI-TOF-MS 
 Mosley  
et al., 2006 
urine SELDI-TOF-MS 
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Rheumatic diseases References Samples Proteomic approach 
 Zhang  
et al., 2008 
 
urine SELDI-TOF-MS 
 Dai et al., 2008 peripheral blood 
mononuclear cells 
2DE/MALDI-TOF-MS 
 
 Dai et al., 2010 serum magnetic beads-based weak 
cation exchange 
chromatography/ MALDI-
TOF-MS 
 Lood et al., 2010 platelets antigen- microarrays 
 Wang  
et al., 2010 
peripheral blood 
mononuclear cells 
Isobaric tagging for relative 
and absolute protein 
quantification (iTRAQ)- 
multiple chromatographic 
fractionation and tandem 
mass spectrometry 
Sjogren’Syndrome Tomosugi 
et al., 2005 
tears SELDI-TOF-MS 
 Ryu  
et al., 2006 
parotid saliva SELDI-TOF-MS/2D-DIGE 
 Giusti  
et al., 2007 
whole saliva 2DE/MALDI-TOF 
 Stea  
et al., 2007 
parotid glands SDS-PAGE 
 Peluso  
et al., 2007 
whole saliva HPLC-ESI/MS 
 Hu et al., 2007b whole saliva 2DE/MALDI-TOF-MS/LC-
MS/MS 
 Fleissig et al., 
2009 
whole saliva 2DE/MALDI-TOF-MS 
 Hjelmervik  
et al., 2009 
minor salivary 
glands 
LC-ESI/MS-MS; 
2DE/MALDI-TOF-MS 
 Hu  
et al.2011 
whole Saliva protein microarrays 
Fybromialgia Bazzichi 
et al., 2009 
whole saliva 2DE/MALDI-TOF 
+ Chronic Fatigue 
Syndrome 
Baraniuk  
et al., 2005 
cerebrospinal fluid capillary chromatography, 
quadrupole-time-of-flight 
mass spectrometry 
Table 1. Proteomics in Rheumatology 
4. Proteomic and Sjogren’s syndrome 
The majority of proteomic studies concerning SS chose saliva as the biological fluid (6 
papers), and only a limited number used tears (1 paper) or salivary gland tissue (3 paper).  
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4.1 Tears 
Histological and functional changes of the lachrymal gland might be reflected in proteomic 
patterns in tear fluids. In SS, a reduced production of aqueous tear was clarified when 
examined by the Schirmer test. Reduction of tear film stability as shown by the tear film 
break-up time test seems to be responsible for a disturbance of the quality of the mucus 
layer composition. However, there was no screening test for the changes in quality of tear 
components, which should accurately reflect the physiologic state of the lachrymal gland 
and the level of its function. The first proteomic trial for carrying out a determination of the 
disease biomarkers in tear fluid for SS was performed by Tomosugi and co-workers 
(Tomosugi et al., 2005). The authors, using surface-enhanced laser desorption/ionisation 
time-of-flight mass spectrometry, identified 10 potential novel proteins that differed 
between SS patients and control subjects. Seven were down regulated, and three correlated 
significantly with SS scores and epithelial damage of the ocular surface. Although these 
investigators have not yet identified the proteins, this study clearly demonstrates how such 
techniques can be applied in identifying specific protein profiles involved in the 
pathophysiological processes associated with SS.  
4.2 Parotid glands tissue 
Proteomic analysis has been applied not only to the study of salivary and lachrymal fluids, 
but also to the study of gland tissues because SS directly affects the glands and because 
autoantibodies characterising SS (anti-Ro/SSA and anti-La/SSB) are produced mainly in 
these affected tissues. Parotid gland extracts of SS patients were then analysed by combining 
conventional immunological methods (2DE and immunoblot) with mass spectrometry in 
order to evaluate modifications of known autoantigens (i.e., La/SSB), and in order to 
determine other targets of the autoimmune response in the parotid glands of SS patients. In 
the work by Stea and co-workers (Stea et al., 2007), in order to identify the isoforms of 
La/SSB in parotid glands of SS patients, an immunoblot with purified anti-La antibodies 
was performed after 2DE of parotid gland extracts from two SS patients. An extract from a 
human salivary gland epithelial cell line and a parotid gland extract from a patient with 
mixed parotid tumour were used as controls. The results of the study revealed that SS 
salivary glands contained high levels of post-translationally modified La/SSB autoantigen, 
degraded from 48 kDa to 34 kDa. The 48 kDa form of the protein was faintly recognised, in 
contrast to normal controls. Moreover, only five distinct La/SSB isoforms were detected in 
SS patients’ specimens, in contrast to seven isoforms in controls. Finally, a new potential 
autoantigen was identified in the parotid glands of SS. A protein at around 45 kDa was 
recognised as a target of autoantibodies by the SS sera. This protein was identified as human 
actin by combining conventional immunological methods and mass spectrometry. 
Moreover, Hjelmervik and colleagues (Hjelmervik et al., 2009) conducted a large-scale 
mapping of the minor salivary gland proteome, applying two complementary methods: the 
LC-ESI-MS/MS and 2DE. The main objective of their work was to achieve a large-scale 
delineation of the minor salivary gland proteome in samples from both SS patients and non-
SS controls. Heat shock proteins, mucins, carbonic anhydrases, enolase, vimentin, and 
cyclophillin B were among the proteins identified. Six proteins were exclusively identified in 
SS patients with respect the controls in particular alpha defensin 1 and calmodulin. A 
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system biology approach has been used by Hu and co-workers (Hu et al., 2009) to study 
parotid gland tissue samples obtained from patients with primary SS, from patients with SS 
/MALT lymphoma, and from subjects without primary SS. The tissue samples were 
assessed by gene-expression microarray profiling and proteomics analysis. The authors 
defined a panel of 8 candidate genes for distinguishing primary SS/MALT lymphoma from 
primary SS. Among the 115 proteins showing >3-fold elevated levels, 20 proteins were up-
regulated in primary SS parotid gland tissue samples as compared with non– primary SS 
control and primary SS/MALT lymphoma parotid gland tissue samples. Twenty-five 
proteins were up regulated in both primary SS and primary SS/MALT lymphoma samples 
as compared with non–primary SS control samples, and 70 proteins were up-regulated in 
primary SS/MALT lymphoma samples as compared with both non–primary SS control and 
primary SS samples. From a functional point of view, the proteins overexpressed in SS were 
related to the immune/defence response, apoptosis, cell-cell adhesion, and anti-oxidative 
stress, whereas many of the proteins with high expression in primary SS/MALT lymphoma 
were related to signal transduction, gene regulation, apoptosis, the immune response, and 
oxidative stress. 
4.3 Saliva 
Human saliva contains a large number of proteins and peptides, which have several 
important biological functions and potentially reflect both oral and systemic health 
conditions. Compared to blood, saliva possesses a smaller amount of proteins with a minor 
risk of non-specific interference. Saliva is an attractive medium for proteomic analysis for 
many different reasons. One of its major advantages is that salivary fluid can be obtained by 
using a non-invasive, simple, safe, and stress-free procedure that can be applied to large 
groups of subjects. The simple nature of saliva collection allows for repetition and multiple 
collection of saliva useful in early diagnosis, monitoring disease progression or treatment 
responses. Finally, this fluid undoubtedly reflects the salivary gland involvement that 
characterises SS disease (primary and secondary), which directly involves the oral cavity 
(Streckfus et al., 2007; Hu et al., 2007a). 
Six studies have been performed in SS, and they are quite different in their principal goals as 
well as in their general methodologies (Ryu et al., 2006; Giusti et al., 2007; Hu et al., 2007b; 
Peluso et al., 2007; Flesseig et al., 2009; Hu et al., 2011). Whole saliva or individual glands 
saliva have been examined, and samples were collected both in stimulated and 
unstimulated conditions. Moreover, differences were present in salivary protein preparation 
and separation. However, although the collection protocol was different, many common 
biomarkers for SS have been found from the five different papers such as actin, Ig gamma-1 
chain C region, beta-2 microglobulin, salivary amylase, carbonic anhydrase VI, prolactin 
inducible protein, calgranulins A and B, and fatty acid binding protein. Table 2 reports the 
proteomic studies performed up to now in saliva, distinguishing the source of this biofluid, 
and the type of proteomic approach. A list of potential biomarkers defined by these studies 
is also shown.  
First, we will report the results obtained in other studies, and then in the following 
paragraph we will discuss our findings.  
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Study Samples/Patients Methods Proteins differentially expressed 
Ryu  
et al., 2006 
stimulated parotid 
saliva/ 
 
primary Sjogren’s 
syndrome 
SELDI-TOF-
MS/2D-DIGE 
2-microglobulin, lactoferrin, Ig  
light chain, l, polymeric Ig receptor 
(PIGR), lysozyme C, cystatin C, 
proline-rich proteins (PRPs), -
amylase, carbonic anhydrase VI 
Giusti  
et al., 2007 
unstimulated whole 
saliva  
 
primary Sjogren’s 
syndrome 
2DE/MALDI-
TOF 
carbonic anhydrase VI, cystatin S, 
cystatin C, cystatin D, calgranulin B, 
cyclophillin A, lipocalin-1, 
phosphatidylethanolammine-
binding protein (PEPB), IgkC 
protein, zinc--glycoprotein, fatty 
acid binding protein (FABP), ACTB, 
-actin fragment, leukocyte elastase 
inhibitor, glutathione-S-transferase, 
-amylase precursor, cystatin SN 
precursor, keratin 6L, prolactine-
inducible protein precursor 
Peluso  
et al., 2007 
unstimulated whole 
saliva  
 
primary and secondary 
Sjogren’s syndrome 
HPLC-ESI-MS acidic and basic proline-rich proteins 
(PRPs), statherins, histatins, and 
cystatins, -defensin 1, -defensin 2, 
statherins 
Hu  
et al.,2007b 
Stimulated whole 
saliva/ parotid, 
submandibular, 
sublingual saliva  
 
primary Sjogren’s 
syndrome 
2DE/MALDI-
TOF-MS/LC-
MS-MS 
 
carbonic anhydrase VI, polymeric 
immunoglobulin receptor, lysozime 
C, prolactin inducible protein, Von 
Ebner’s gland protein, cystatin C, 
cystatin SN, cystatin D, cystatin S, 
cystatin SA, calgranulin A, 
calgranulin B, psoriasin, hemoglobin 
-chain, hemoglobin -1-globin 
chain, fatty acid binding protein 
epidermal, Ig--1 chain C, Ig  chain 
C region (IGHM), -enolase, salivary 
-amylase, fructose-biphosphate 
aldolase A, carbonic anhydrase I, 
carbonic anhydrase II, caspase 14,  
2-microglobulin, actin,  
serum albumin 
Fleissig  
et al.,2009 
unstimulated whole 
saliva  
 
primary and secondary 
Sjogren’s syndrome 
2DE/ESI-MS-
MS 
 
calgranulin B, calgranulin A, Ig--1 
chain C, -actin, serum albumin, 
keratine type I cytoskeletal,  
-actin-1, -amylase,  
vitamin D, polymeric-
immunoglobulin receptor 
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Study Samples/Patients Methods Proteins differentially expressed 
Hu S  
et al., 2011 
unstimulated whole 
saliva 
 
primary Sjogren’s 
syndrome 
protein 
microarrays 
24 saliva autoantibodies: Bcl2 
modifying factor, cardiolipin, 
chromosome X orf56, hypothetical 
protein DKFZp761G2113, Jun 
dimerization protein p21SNFT, 
La/SS-B, Lectin galactoside binding 
soluble 3, Lectin galactoside binding 
soluble 7, Megacaryocite-associated 
tyrosine Kinase, melanoma antigen 
family B 4, mesenchyme homeobox 
1, NEFA-interacting nuclear protein, 
olfactory receptor family 6 N2, outer 
dense fiber of sperm tails 2, plasma 
membrane proteolipid, protein 
kinase C, ribosomal protein S6 
kinase, Ro52/SS-A, SERPINA 3, 
small inducible cytokine subfamily 
E1, testis specific 10, TAO kinase 3, 
transglutaminase, Unfrac whole 
histone 
Table 2. Saliva and Proteomic studies of Sjogren’s syndrome. 
The pilot study of proteomic applied to SS saliva was performed in 2006 by Ryu and co-
workers. Using SELDI-TOF and 2D difference gel electrophoresis (2D-DIGE), they analysed 
stimulated parotid saliva from five healthy volunteers, 41 primary SS patients, and 20 non-
SS subjects, including 15 non-SS subjects with complaints of xerostomia who, nonetheless, 
did not meet the diagnostic criteria for SS. Combining these two approaches, the authors 
focused their attention on ten differentially expressed proteins and, in particular, they 
identified significant increases of -2 microglobulin, lactoferrin, Ig -light chain, polymeric 
Ig receptor, lysozyme C, and cystatin C. They also found in the patient group a reduction of 
amylase, carbonic anhydrase VI and of two presumed proline-rich proteins. Moreover, they 
found no association between the focus score and any biomarker. Lactoferrin and  
2-microglobulin showed the greatest increases, but because their levels have been reported 
to increase also in other inflammatory diseases affecting salivary glands, the authors related 
these proteins to aspecific salivary gland inflammatory activity. More intriguingly, the 
increased levels of Ig -light chains were explained by the authors as being related to the 
increase in the intra-glandular immunoglobulin synthesis of the disease. Finally, the 
decrease of the two proline-rich proteins and -amylase were ascribed to acinar 
parenchymal damage, while the reduction in carbonic anhydrase VI was reported as in line 
with a recent report on its decreased gene expression in SS minor gland biopsies.  
Next, a profile of potential salivary proteomic and genomic biomarkers for SS was depicted 
by Hu and co-workers (Hu et al., 2007b). Sixteen WS proteins were found to be down-
regulated, and 25 WS proteins were found to be up-regulated in SS patients compared with 
matched healthy control subjects. Moreover, using gene chip followed by real time PCR 
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analysis of whole saliva, Hu and co-workers revealed factors such as interferon (IFN) and 
IFN-inducible protein G1P2 specifically expressed in SS patients. One of the important 
findings of this study was that many up-regulated genes were involved in the IFN pathway, 
suggesting the involvement of viral infection in SS pathogenesis.  
Peluso and colleagues (Peluso et al., 2007) analysed the differences in the salivary protein 
profiles of primary SS and secondary SS patients, and of control subjects using HPLC-ESI-
MS. The authors collected whole saliva specimens from 9 primary SS patients, 9 secondary 
SS patients (3 Rheumatoid Arthritis-2° SS; 3 systemic sclerosis-2° SS; 3 systemic lupus 
erythematosus-2° SS), and 10 healthy controls, and they analysed the levels and frequencies 
of 62 proteins. The analysis focused mainly on low molecular weight proteins represented 
by acid and basic proline-rich proteins, statherins, histatins, cystatins, lysozyme, and 
defensins. In the second part of the study, the authors examined the effect of pilocarpine on 
the salivary peptide and protein profiles in a subgroup of 6 primary SS patients. They found 
that the basic and acid proline-rich proteins and the statherins had the best response to the 
pilocarpine treatment, while the salivary cystatin and histatin protein classes were modified 
less. In the comparison between primary and secondary SS salivary profiles, the researchers 
outlined that patients with secondary SS showed a protein profile that was intermediate 
between that of the primary SS patients and the healthy subjects. In particular, salivary 
cystatins (C, S, S2, SA, and SN) and histatins (2, 3, 4, 7, 9, 11 and 12) were less frequently 
identifiable in primary and secondary SS patients versus controls. On the other hand,  
3 proteins (IB-6, P-B Des1-4, and -defensin 2) were identifiable in a significantly higher 
percentage of secondary SS patients than in the controls. In particular, -defensin 2 was 
found in 6 of the primary SS patients, in 3 of the 9 secondary SS patients, and in none of the 
controls. Finally, IB-1 and statherin showed significantly lower levels in secondary SS than 
in the controls. 
Additional information was reported by Flesseig and colleagues (Flesseig et al., 2009), who 
in a preliminary individual saliva sample analysis showed that SS patients (six SS patients as 
well as one symptomatic subject not fulfilling the criteria completely, and one who had 
developed follicular lymphoma) exhibited two patterns of protein expression with an 
indirect relation to the clinical serological or histological severity of disease.  
Recently, Hu and co-workers (Hu et al., 2011) have demonstrated the potential of the high-
throughput protein microarray approach in the discovery of autoantibody biomarkers for 
the non-invasive diagnosis of SS. Saliva autoantibodies present in patients with SS or 
systemic lupus erythematosus and healthy control subjects were profiled with protein 
microarrays. After comparison with controls (systemic lupus erythematosus and healthy 
subjects), statistical analysis of the microarray data revealed 24 autoantibody biomarkers 
that could differentiate SS from both control groups. A validation of four of these 
autoantibodies (anti-SSA, anti-SSB, anti-transglutamine, anti-histone) was performed using 
commercial ELISA kits. Although these are known autoantibodies in SS, they were usually 
tested in serum samples. The authors suggest that testing these autoantibodies in saliva may 
be valuable for the diagnosis of SS. Therefore, up to now a wide spectrum of proteins has 
been identified that might include both “true” disease biomarkers, as well as specific 
markers of tissue damage (i.e., actin) or inflammation (calgranulins). Therefore, we can 
hypothesise that further studies might shed some light on this aspect. 
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4.3.1 Our results 
In 2005, we began to study rheumatic diseases using a proteomic approach. In our studies, 
whole saliva was chosen as the biological fluid to discover specific disease biomarkers for 
primary and secondary manifestations of SS and also of other correlated rheumatic diseases 
such as systemic sclerosis (Giusti et al., 2007; Baldini et al., 2008), fybromialgia (Bazzichi et 
al., 2009) and rheumatoid arthritis (Giusti et al., 2010). In our work on SS, we analysed the 
whole saliva of 12 primary SS patients in comparison with 12 healthy controls by using 
quantitative 2DE experiments combined with MALDI-TOF-MS for protein identification 
(Giusti et al., 2007). In particular, in this study, by comparing the SS with control classes, we 
found that 4 proteins were unique to the control samples (carbonic anhydrase VI, cystatins 
S, C precursor and cystatin D), and 6 proteins were unique to the SS samples (calgranulin B, 
cyclophilin A, lipocalin-1 precursor, phosphatidyl ethanolammine binding protein, Ig kappa 
chain C region (IGKC), protein and Zinc--2 glycoprotein precursor). Moreover, in 
evaluating the mean ± SD of the percentage of the volume of each single protein of the 
analytical (not synthetic) gels, the authors also discovered that 10 protein spots were up-
regulated with > 2-fold changes (fatty acid binding protein (E-FABP), ACTB protein, -actin 
fragment, leukocyte elastase inhibitor, glutathione-S-transferase (GST), and 5 unidentified 
proteins). On the other hand, 4 were down regulated (-amylase precursor, cystatin SN 
precursor, keratin 6L, prolactin-inducible protein precursor) in SS patients compared with 
controls. These results confirmed the decrease of some of the typical acinar proteins and the 
increase of many inflammatory proteins. Moreover, they outlined the relevance of proteins 
not previously described i.e., PIP, keratin 6L, and lipocalin, as markers of acinar damage and 
oral environment alteration. This study was the basis for further investigations aimed at 
characterising possible differences in salivary protein profiles in patients who have 
connective tissue diseases associated with secondary SS. Therefore, we extended the study 
to refine the diagnostic power of a panel of candidate salivary biomarkers described in  
SS with respect to both healthy volunteers and pathological controls (sicca syndrome). 
Moreover, the aim of the study was also to explore the biological and pathogenetic functions 
of the putative salivary proteomic biomarkers, both in the local exocrinopathy and in the 
systemic inflammatory autoimmune systemic processes of SS. Our preliminary results, to be 
published, suggest that novel, non-invasively-collected salivary proteomic biomarkers 
might be helpful in an early and accurate characterisation of primary and secondary SS. In 
addition, some of the secondary SS identified biomarkers apparently reflected not only the 
SS component, but also the concomitant systemic autoimmune disorders, shedding new 
light on the potential diagnostic role of saliva in autoimmune diseases irrespectively of 
salivary gland involvement.  
The capacity of whole saliva to reflect systemic conditions was also suggested from the 
preliminary unpublished results of a case study on the salivary proteome of non-Hodgkin’ 
lymphomas. We observed that clinical and functional changes of the salivary glands driven 
by autoimmune and lymphoproliferative processes might be reflected in patients’ whole 
saliva proteins, and that there was a specific correspondence between clinical improvement 
and proteomic changes of the salivary peptide complex. These observations indicate the 
potential usefulness of proteomic analysis in discovering not only diagnostic but also 
prognostic and therapeutic biomarkers for patients with primary SS and non-Hodgkin’s 
www.intechopen.com
 
Sjögren’s Syndrome: The Proteomic Approaches 
 
205 
lymphomas. Therefore, we speculate that during the follow-up of patients with lymphomas, 
proteomic analysis might be able to use the salivary biomarkers as early predictors of 
treatment response. From the perspective of the research, the analysis of biomarker 
signatures in saliva could also help to clarify the pathogenetic pathways underlying 
lymphoproliferation in SS, leading to the development of new methods in early diagnosis 
and curative therapies. 
 
Fig. 1. Protein-protein interaction network of regulated pSS-associated proteins identified in 
at least two proteomic studies found differentially expressed in saliva. The STRING tool 
(http://string-db.org/) was used making the network with the following proteins: -2-
microglobulin, polymeric Ig receptor (PIGR), salivary acidic proline-rich phosphoprotein 1 
(PRH1) and 2 (PRH2), -amylase, carbonic anhydrase VI, Cystatin SA (CST2), Cystatin SN 
(CST1), Cystatin C (CST3), Cystatin S (CST4), Cystatin D (CST5), LCN1, Calgranulin A 
(S100A8), Calgranulin B (S100A9), Psoriasin (S100A7), Fatty acid-binding protein, epidermal 
(FABP5), IGKC (LOC652493), Ig -1 chain C region (IGHG1), -Actin (ACTB), Fc fragment of 
IgG, receptor, transporter (FCGRT), leukocyte immunoglobulin-like receptor (LILRB1), HLA 
class I histocompatibility antigen, alpha chain G (ENSG00000237216) , major 
histocompatibility complex class IA (HLA-A) major histocompatibility complex class IB 
(HLA-B) and glycoprotein hormones, alpha polypeptide (CGA). In the figure is shown the 
potential interaction with additional proteins with score values ranging from 0.993 to 0.999. 
The different clusters are indicated by the same colour. The thickness of the connecting lines 
indicates the level of confidence. 
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5. Conclusions  
SS lacks any true diagnostic criteria for primary and secondary manifestations as well as a 
set of activity criteria. The risk of misdiagnosis is still quite high, and it highlights the need 
for a more definitive set of tests and criteria to classify these patients. One possible solution 
is the proteomic approach, which might represent a promising tool to explore biomarkers 
for diagnostic aims. Until now, the studies performed have been carried out on parotid 
biopsies, tears, and saliva. Saliva represents an attractive medium for proteomic analysis 
because its composition is not complex, and it reflects more accurately the current state of 
the organism at any moment. Moreover, it presents many logistical advantages because the 
collection is not invasive, and may be repeated for monitoring over time. However, the 
identification of true biomarkers of primary and secondary SS is still in its infancy. The 
results obtained from different studies have not yet defined a conclusive panel of 
biomarkers useful in diagnostic purposes. Nonetheless, some conclusions can be drawn: SS 
patients showed a decrease of proteins of glandular origins and an increase of inflammatory 
proteins, while the salivary profile of secondary SS is intermediate between that of primary 
SS patients and healthy subjects. Figure 1 shows a representative interactive network 
obtained by STRING analysis among the proteins found differentially expressed in the 
proteomic studies performed in saliva. In addition to identifying proteins, we enlarged the 
network to obtain a large interactive network with more nodes. Interestingly, the figure 
shows that -2 microglobulin, which is the invariant chain of the Major Histocompatibility 
Complex class I molecules, considered as a marker of B cell activation, is the key node of the 
main cluster.  
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